A multi-dose Phase 1b to evaluate the tolerability and PK profile of three ascending doses of ADS-4101 administered once daily at bedtime compared to ascending doses of twice daily VIMPAT tablets

Trial Profile

A multi-dose Phase 1b to evaluate the tolerability and PK profile of three ascending doses of ADS-4101 administered once daily at bedtime compared to ascending doses of twice daily VIMPAT tablets

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Lacosamide (Primary) ; Lacosamide
  • Indications Epilepsy
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 27 Apr 2018 Results of two phase 1 studies (CTP: 278641 and CTP:285253) assessing pharmacokinetic evaluations of ADS-4101 (Lacosamide) Modified Release Capsules versus Lacosamide immediate release presented presented at the 70th Annual Meeting of the American Academy of Neurology.
    • 05 Dec 2017 Status changed from recruiting to completed, according to results presented at the 71st Annual Meeting of the American Epilepsy Society.
    • 05 Dec 2017 Results presented at the 71st Annual Meeting of the American Epilepsy Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top